Tomer Babu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Tomer Babu has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
- Dan Gibson
Institute for Drug Research, School of Pharmacy, The Hebrew University, Jerusalem 91120, Israel
10 shared publications - Valentina Gandin
Dipartimento di Scienze del Farmaco, Università di Padova, via Marzolo 5, 35131 Padova, Italy
6 shared publications - Subhendu Karmakar
Institute for Drug Research, School of Pharmacy, The Faculty of Medicine, The Hebrew University of Jerusalem, Jerusalem 9112102, Israel
4 shared publications - Amrita Sarkar
Institute for Drug Research School of Pharmacy The Hebrew University of Jerusalem Jerusalem 9112102 Israel
3 shared publications - Claudia Schmidt
Chair of Medicinal and Bioinorganic Chemistry, Department of Chemistry, School of Natural Sciences, Technical University of Munich, Garching, Germany
3 shared publications - Hana Kostrhunova
Czech Academy of Sciences, Institute of Biophysics, CZ-61200 Brno, Czech Republic
3 shared publications
Latest Publications
- Open Access
- 10 April 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (35) , 8952-8955
A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures
A next-generation Pt( iv )–Au( i ) multimetal complex incorporating gemcitabine enhances cytotoxicity and ICD. RNA-seq pathway analysis reveals transcriptomic signatures predictive of ICD potential (created in BioRender, T. Babu).
- 10 April 2026
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 62 (35) , 8952-8955
Open AccessA next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures
A next-generation Pt( iv )–Au( i ) multimetal complex incorporating gemcitabine enhances cytotoxicity and ICD. RNA-seq pathway analysis reveals transcriptomic signatures predictive of ICD potential (created in BioRender, T. Babu).
- Open Access
- 12 August 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (39)
Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death
Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.
- 12 August 2025
- Published by Wiley in Angewandte Chemie
- Vol. 137 (39)
Open AccessThree Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death
Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.
- Open Access
- 12 August 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (39) , e202514351
Three Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death
Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.
- 12 August 2025
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 64 (39) , e202514351
Open AccessThree Is Better than One: A Multimetal Complex that Triggers Immunogenic Cell Death
Immunogenic cell death (ICD) is a form of regulated cell death capable of stimulating an adaptive immune response through release of damage‐associated molecular patterns (DAMPs). While several metal complexes have shown promise as ICD inducers, conjugates containing more than one metal center remain to be explored for ICD. Here, we report the design, synthesis, and evaluation of a tri‐metallic Au I ‐Pt IV ‐Ru II prodrug ( 5 ) that codelivers oxaliplatin (Type I ICD inducer), Ru II arene 2‐pyridinecarbothioamides (Type I), and Au(I) bis‐N‐heterocyclic (Type II) using a single scaffold. Upon reduction, complex 5 releases all three cytotoxic species, resulting in enhanced inhibition of thioredoxin reductase (TrxR1&2), elevated production of reactive oxygen species (ROS), and in vitro DAMP release. In vivo studies of complex 5 in a colorectal cancer mouse model demonstrated tumor growth suppression, reduced off‐target metal accumulation, and improved immune memory in a tumor challenge study compared to a 1:1:1 mixture of the constituent agents. Furthermore, peripheral white blood cell (WBC) profiling revealed that complex 5 activates both the innate and adaptive immune compartments. This study demonstrates an integrated chemo‐immunotherapeutic strategy that unifies multiple ICD triggers within a single prodrug framework. It thus highlights a promising approach to the creation of metal‐based multimodal anticancer therapies.
- Open Access
- 18 January 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 183, 117854
Cisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy
- 18 January 2025
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 183, 117854
Open AccessCisplatin-eugenol Pt(IV) prodrugs target colon cancer stem cells: A novel strategy for enhanced anticancer efficacy
- Open Access
- 8 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (2) , 1608-1618
Multitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain
Cisplatin and oxaliplatin are Pt(II) anticancer agents that are used to treat several cancers, usually in combination with other drugs. Their efficacy is diminished by dose-limiting peripheral neuropathy (PN) that affects ∼70% of patients. PN is caused by selective accumulation of the platinum drugs in the dorsal root ganglia (DRG), which overexpress transporters for cisplatin and oxaliplatin. To date, no drug is recommended for the prevention of PN. We report that Pt(IV) prodrugs of cisplatin or oxaliplatin do not induce neuropathic pain in mice, likely due to the lower accumulation of platinum in the DRG compared with Pt(II) drugs. Moreover, the multitargeting prodrug that combines cisplatin with paclitaxel, both strong inducers of PN, efficiently inhibited tumor growth in vivo without inducing neuropathic pain. The high antitumor efficacy of Pt(IV) prodrugs and their micellar counterparts and the low level of neuropathic pain associated with them make them ideal candidates for clinical use in cancer therapy.
- 8 January 2025
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 68 (2) , 1608-1618
Open AccessMultitargeting Pt(IV) Derivatives of Cisplatin or Oxaliplatin Inhibit Tumor Growth in Mice without Inducing Neuropathic Pain
Cisplatin and oxaliplatin are Pt(II) anticancer agents that are used to treat several cancers, usually in combination with other drugs. Their efficacy is diminished by dose-limiting peripheral neuropathy (PN) that affects ∼70% of patients. PN is caused by selective accumulation of the platinum drugs in the dorsal root ganglia (DRG), which overexpress transporters for cisplatin and oxaliplatin. To date, no drug is recommended for the prevention of PN. We report that Pt(IV) prodrugs of cisplatin or oxaliplatin do not induce neuropathic pain in mice, likely due to the lower accumulation of platinum in the DRG compared with Pt(II) drugs. Moreover, the multitargeting prodrug that combines cisplatin with paclitaxel, both strong inducers of PN, efficiently inhibited tumor growth in vivo without inducing neuropathic pain. The high antitumor efficacy of Pt(IV) prodrugs and their micellar counterparts and the low level of neuropathic pain associated with them make them ideal candidates for clinical use in cancer therapy.
- Open Access
- 6 December 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 11 (2) , 534-548
Stepwise optimization of tumor-targeted dual-action platinum( iv )-gemcitabine prodrugs
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.
- 6 December 2023
- Published by Royal Society of Chemistry (RSC) in Inorganic Chemistry Frontiers
- Vol. 11 (2) , 534-548
Open AccessStepwise optimization of tumor-targeted dual-action platinum( iv )-gemcitabine prodrugs
An albumin-binding cisplatin( iv )-gemcitabine complex was step-by-step improved based on stability, reduction, albumin-binding and in vivo data yielding a carboplatin( iv ) complex with distinctly improved overall survival and anticancer activity.
- Open Access
- 12 September 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (42) , e202310774
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
- 12 September 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (42) , e202310774
Open AccessMultitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
- Open Access
- 11 September 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (42)
Multitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
- 11 September 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (42)
Open AccessMultitargeting Prodrugs that Release Oxaliplatin, Doxorubicin and Gemcitabine are Potent Inhibitors of Tumor Growth and Effective Inducers of Immunogenic Cell Death
A multitargeting prodrug (2) that releases gemcitabine, oxaliplatin, and doxorubicin in their active form in cancer cells is a potent cytotoxic agent with nM IC50s; it is highly selective to cancer cells with mean selectivity indices to human (136) and murine (320) cancer cells. It effectively induces release of DAMPs (CALR, ATP & HMGB1) in CT26 cells facilitating more efficient phagocytosis by J774 macrophages than the FDA drugs or their co‐administration. The viability of CT26 cells co‐cultured with J774 macrophages and treated with 2 was reduced by 32 % compared to the non‐treated cells, suggesting a synergistic antiproliferative effect between the chemical and immune reactions. 2 inhibited in vivo tumor growth in two murine models (LLC and CT26) better than the FDA drugs or their co‐administration with significantly lower body weight loss. Mice inoculated with CT26 cells treated with 2 showed slightly better tumor free survival than doxorubicin.
- Open Access
- 31 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (10)
Oral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity
AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.
- 31 January 2023
- Published by Wiley in Angewandte Chemie
- Vol. 135 (10)
Open AccessOral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity
AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.
- Open Access
- 31 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (10) , e202217233
Oral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity
AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.
- 31 January 2023
- Published by Wiley in Angewandte Chemie International Edition
- Vol. 62 (10) , e202217233
Open AccessOral Anticancer Heterobimetallic PtIV−AuIComplexes Show High In Vivo Activity and Low Toxicity
AuI‐carbene and PtIV−AuI‐carbene prodrugs display low to sub‐μM activity against several cancer cell lines and overcome cisplatin (cisPt) resistance. Linking a cisPt‐derived PtIV(phenylbutyrate) complex to a AuI‐phenylimidazolylidene complex2, yielded the most potent prodrug. While in vivo tests against Lewis Lung Carcinoma showed that the prodrug PtIV(phenylbutyrate)‐AuI‐carbene (7) and the 1 : 1 : 1 co‐administration of cisPt: phenylbutyrate:2efficiently inhibited tumor growth (≈95 %), much better than2(75 %) or cisPt (84 %),7exhibited only 5 % body weight loss compared to 14 % for2, 20 % for cisPt and >30 % for the co‐administration.7was much more efficient than2at inhibiting TrxR activity in the isolated enzyme, in cells and in the tumor, even though it was much less efficient than2at binding to selenocysteine peptides modeling the active site of TrxR. Organ distribution and laser‐ablation (LA)‐ICP‐TOFMS imaging suggest that7arrives intact at the tumor and is activated there.